Sublingual immunotherapy not effective in house dust mite-allergic children in primary care

To cite this article: de Bot CMA, Moed H, Berger MY, Röder E, Hop WCJ, de Groot H, de Jongste JC, van Wijk RG, Bindels PJE, van der Wouden JC. Sublingual immunotherapy not effective in house dust mite–allergic children in primary care. Pediatr Allergy Immunol 2011; Doi: 10.1111/j.1399‐3038.2011.0121...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric allergy and immunology Vol. 23; no. 2; pp. 151 - 159
Main Authors: de Bot, Cindy M. A., Moed, Heleen, Berger, Marjolein Y., Röder, Esther, Hop, Wim C. J., de Groot, Hans, de Jongste, Johan C., Gerth van Wijk, Roy, Bindels, Patrick J. E., van der Wouden, Johannes C.
Format: Journal Article
Language:English
Published: Oxford, UK Blackwell Publishing Ltd 01.03.2012
Blackwell
Wiley Subscription Services, Inc
Subjects:
ISSN:0905-6157, 1399-3038, 1399-3038
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To cite this article: de Bot CMA, Moed H, Berger MY, Röder E, Hop WCJ, de Groot H, de Jongste JC, van Wijk RG, Bindels PJE, van der Wouden JC. Sublingual immunotherapy not effective in house dust mite–allergic children in primary care. Pediatr Allergy Immunol 2011; Doi: 10.1111/j.1399‐3038.2011.01219.x Background:  Sublingual immunotherapy (SLIT) as a therapy for the treatment of allergic rhinitis in children might be acceptable as an alternative for subcutaneous immunotherapy. However, the efficacy of SLIT with house dust mite extract is not well established. Objective:  To investigate whether SLIT in house dust mite–allergic children recruited in primary care is effective and safe. Methods:  Children aged 6–18 years (n = 251) recruited in primary care with a house dust mite–induced allergic rhinitis received either SLIT or placebo for 2 years. Symptoms and medication use were assessed throughout the study. Primary outcome parameter was the mean total nose symptom score (scales 0–12) during the autumn of the second treatment year. Safety was assessed by recording any adverse event. Results:  Overall, the mean nose symptom score ± s.d. after 2 years of treatment showed no significant effect of SLIT (symptom score intervention group 2.26 ± 1.84 vs. placebo group, 2.02 ± 1.67; p = 0.08). There were no significant differences in secondary outcomes, nor in subgroup analyses. The number of patients reporting adverse events was comparable between both groups. Conclusions:  Sublingual immunotherapy with house dust mite allergen was not better than placebo in reducing rhinitis symptoms in house dust mite–allergic children in primary care. SLIT as administered in this study can be considered safe.
Bibliography:ArticleID:PAI1219
istex:DCCF1B0D51B31CB22FF12FC3653489D6DC3DF020
ark:/67375/WNG-DBQ01GG3-3
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0905-6157
1399-3038
1399-3038
DOI:10.1111/j.1399-3038.2011.01219.x